In the present study, proteins differentially expressed between gastric cancer tissue and para-tumoral normal gastric tissues were screened, and the function of the highly expressed protein c1QTNF6 in gastric carcinoma was investigated. The differential expression of mRNAs extracted from the tumor and adjacent tissues was analyzed using Genechip assay. An AGS si-c1QTNF6 cell line was constructed using shRNA-c1QTNF6 lentivirus. The cell invasion and migration ability of c1QTNF6-knockdown cells were determined by Transwell chamber migration and wound healing assays, respectively. The effects of c1QTNF6 on AGS cell cycle distribution and apoptosis were detected using a FACScan flow cytometer. The results demonstrated that the expression of 109 genes was increased and the expression of 129 was decreased in tumor tissues. Among these genes, the c1QTNF6 gene was highly expressed in tumor tissues and the AGS7901 cell line. c1QTNF6-knockdown decreased the cell growth, and the proliferative and migration ability, as well as increasing the apoptosis of gastric carcinoma cells. In addition, the number of AGS cells in the G2/M phase was significantly increased after 5 days of c1QTNF6-shRNA lentivirus infection. The results of the present study indicated that c1QTNF6 serves an important role in the development of gastric carcinoma. c1QTNF6 is involved in promoting the proliferation and migration, and in reducing the apoptosis of gastric carcinoma cells. These results provided a potential therapeutic target for the treatment of gastric carcinoma.

BackgroundThis retrospective cohort study aimed to evaluate the clinical outcomes of H101 combined with chemotherapy for advanced gastric carcinoma (GC) patients.MethodsThe advanced GC patients, who were treated with H101 and/or chemotherapy, were enrolled and divided into three groups according to treatment method. The clinical characteristics of patients, clinical short-term and long-term outcomes, followed up, and complication were analyzed.ResultsA total of 95 patients (30 patients in group A were treated with H101, 33 in group B patients were treated with chemotherapy, 32 patients in group C were treated with H101 combined with chemotherapy) were retrospectively reviewed. The disease control rate (DCR) and overall response rate (ORR) were significantly greater in group C (81.3% and 50.0%) than in groups A (63.3% and 30.0%) and B (66.7% and 33.3%, all p < 0.05). The 1- and 2-year survival rates and progression-free survival were significantly greater in group C than in groups A and B (all p < 0.05). There was no significant difference in complication among the three groups. At dose levels of 0.5 × 1012 vp/day, 1.0 × 1012 vp/day, and 1.5 × 1012 vp/day, complications were not increased as increased of dose.ConclusionsH101 combined with chemotherapy may be a potential therapeutic option for patients with advanced GC, and prospective studies with proper assessment of toxicity will be needed in the future.

Background/Aims: Renal calculi, or kidney stones, are masses made of crystals that affect people of all geographical, cultural, and racial groups. We conduct this study with the aim of comparing the efficacy of various surgical methods in the treatment of renal calculi. Methods: Controlled clinical trials (CCTs) related to different surgical treatment approaches for renal calculi were included in this study by retrieving them from electronic English databases. The odds ratios (OR), the weighted mean difference (WMD), 95% confidence intervals (95% CI) and surface under the cumulative ranking curves (SUCRA) were evaluated, followed by a cluster analysis. Results: Compared with the extracorporeal shockwave lithotripsy (SWL), minimally invasive percutaneous nephrolithotomy (mini-PCNL), retrograde intrarenal surgery (RIRS), standard percutaneous nephrolithotomy (standard PCNL), ureterorenoscopy (URS) and micro-percutaneous nephrolithotomy (microperc) regimens, the open anatrophic nephrolithotomy (Open AN), URS + RIRS and laparoscopic pyelolithotomy (LP) surgical procedures all presented with a higher stone-free rate in renal calculi. Lower auxiliary procedures were found in the URS + RIRS treatment approach compared with SWL, RIRS, URS and microperc regimens. In addition, the SWL regimen indicated a lower stone-free rate than the mini-PCNL, standard PCNL, Open AN, URS + RIRS and LP regimens. Finally, the RIRS regimen presented with the shortest in-patient stay compared to the mini-PCNL, standard PCNL, Open AN, URS, URS + RIRS and LP regimens. Conclusion: This meta-analysis demonstrated that the URS + RIRS surgical procedure has the best stone-free rate and the lowest number of auxiliary procedures. The RIRS and Microperc both have the shortest hospital stay and operative time.

In the original article, there were three errors in the text.Firstly, the dissolution of H101 was incorrectly stated. A correction has been made to Materials and Methods section, "Treatment Procedures", Paragraph 1:"H101 (-20°C, Shanghai Sunway Biotech, Shanghai, China) was then dissolved with normal saline to 30% of the estimated tumor volume at room temperature, was peritumorally injected via endoscopy according to the manufacturer's instructions, and these injections were repeated 21 days as one treatment cycle".Secondly, the dose of H101 for patients with one lesion with a maximum diameter of ≤5 cm was incorrectly stated. A correction has been made to Materials and Methods section, "Treatment Procedures", Paragraph 2:"The doses of H101 depended on tumor size and the number of lesions: (1) 0.5 × 10 12 virus particles (vp)/day (1 unit) for patients with one lesion with a maximum diameter of ≤5 cm; (2) 1.0 × 10 12 vp/day (2 units) for patients with one lesion with a maximum diameter of 5-10 cm or two lesions with a sum of the diameters of 5-10 cm; (3) 1.5 × 10 12 vp/day (3 units) for patients with one lesion with a maximum diameter >10 cm or ≥ three lesions; (4) for patients with two or more lesions, the dose of H101 for each lesion was further decided by the proportion and size of the different lesions. The number of cycles of H101 was determined according to the instructions for the use of H101 and patients' effect after injection. After injection of H101, renin (0.1 mg/ml) and thrombin (10-100 unit/mL) were sprayed to stop the bleeding".